Advestra advised UBS in connection with its role as sole global coordinator within Rieter Holding’s capital increase. The operation’s gross proceeds reached CHF 400 million approximately. The transaction featured a rights offering and a
Kellerhals Carrard advised the Stef Group, a listed company active in logistics and transport of food products with headquarters in France, on the acquisition of Swiss food transport company Christian Cavegn by the Group’s
Wenger Vieli advised the shareholders of Tripleblue, a provider of AI solutions with a focus on HOA management, in connection with its sale to property-tech specialist Aareon. The Wenger Vieli team Partner Michael Baier (corporate/
Walder Wyss advised Fielmann Group and tele-ophthalmology platform Ocumeda, as the the first agreed to sell a 10% stake in Ocumenda to Zeiss Vision Care. The deal implied a total company valuation of EUR 100m, with
Vischer advised globally active asset manager Blue Owl on an up to USD 500 million term loan facility for Madrigal Pharmaceuticals, a biopharmaceutical company specialised in therapeutics for metabolic dysfunction-associated steatohepatitis. The Vischer team Adrian Dö
Homburger advised UBS Group on its issuance of AUD 1.25 bn Tier 1 capital notes with an equity conversion feature. The issuance The notes are ‘high-trigger’ regulatory capital instruments that count toward UBS Group’s Swiss going-concern
Welcome to our weekly newsletter appointment with Signed, Sealed, Weekend. Let’s see what happened across the Swiss legal market. Lenz & Staehelin advised Prof. Dr. Martin Janssen in connection with the sale of Ecofin
Kevin M. Hubacher (pictured) is Vischer’s latest partnership addition, effective October 1, 2025. The profile Moving from MLL Legal, Hubacher is an expert in M&A/private equity transactions, venture capital investments, restructurings and corporate
Lenz & Staehelin advised private equity healthcare specialist Archimed on its acquisition of a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both active in the biologic therapeutics sector. The deal
Homburger advised 21Shares on the listing of three new series of crypto-linked exchange ETPs as well as the cross-listing of three existing series of crypto-linked ETPs – all on the SIX Swiss Exchange. The series Amognst
